SK bioscience’s membership in associations and global initiatives is as follows.
Global Initiatives and Memberships
|Status of Participation|
|Korea Pharmaceutical and Bio-Pharma Manufacturers Association|
|Korea Biotechnology Industry Organization|
|Korea Biomedicine Industry Organization|
|International Vaccine Institute(IVI)|
|Developing Countries Vaccine Manufactures Network(DCVMN)|
|TCFD(Task Force on Climate-Related Financial Disclosures)|
2022 KCGS Integrated Evaluation
With high transparency and expertise, the Korea Corporate Governance Service (KCGS) has been conducting corporate governance assessments since 2003. In 2011, KCGS began assessing ESG management to evaluate sustainability levels of listed companies in South Korea. Its ESG evaluation model not only conforms to international standards such as OECD Principles of Corporate Governance and ISO26000, but also faithfully reflects the domestic legal system and management environment.
2023 MSCI ESG Ratings
MSCI(Morgan Stanley Capital International), which has been providing ESG evaluation since 1999, evaluates ten topics and thirty-five core issues by ESG area, and gives evaluation results in seven grades from AAA to CCC. A weight is given to the governance evaluation, and in addition to the overall evaluation rating, a separate rating is given for each ESG area.
Awards and Certifications
In accordance with the guidelines of the Task force on Climate-related Financial Disclosures, SK bioscience discloses the impact of climate change on corporate financials every year.
Participation period: 2022
Obtained COVID-19 vaccine manufacturing and quality certification in 2021-2022
Local Government Award
Awarded by Andong City in recognition of social value realization in connection with the region in 2019
Medical Korea Grand Prize
Received a total of six awards in recognition of vaccine development from 2012 to 2019
Acquired ISO 45001, the international standard for L HOUSE safety and health in 2018
SK bioscience systematically manages the environmental impact of all company activities, products, and services by introducing a global standard environmental management system. The company complies with requirements to protect the environment in accordance with regulations and procedures. We also check whether our compliance measures are well-implemented and make efforts to realize improvements every year.
Participation period : 17 Nov. 2022
SK bioscience introduces a global standard information security management system, preemptively manages and protects information and assets, and strives to comply with legal requirements.
Osong New Drug Award/Minister of Food and Drug Safety Prize
Recognized for the development of the world’s first cell-culture quadrivalent inactivated influenza vaccine, “SKY Cellflu Quadrivalent Prefilled Syringe” in 2016. Received a total of two awards in recognition of its contribution to localization of vaccines in 2018
Gold Rating Certified by LEED in the U.S.
Received the world’s first gold grade given to a pharmaceutical factory from LEED (Leadership in Energy and Environmental Design), an eco-friendly building certification system in the United States in 2013.